Medication info

Vicozaplusef Tablet

Prescription medicationExpired
Ingredient · strength
Losartan Potassium›Strength being verifiedHydrochlorothiazide›Strength being verified
Manufacturer / importer
Bionex Co., Ltd.
Appearance
Light yellow oval film-coated tablet
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Expired

MFDS item code 201801456 · Approved 2018.04.02

This product's status changed to Expired on 2023.04.02. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of hypertension not controlled with monotherapy
Who uses it
Adults · Children
Adult dosage
○ Adults The usual dose of this drug is 1 tablet containing losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg per day are not recommended. The maximum antihypertensive effect generally occurs approximately 3 weeks after the start of treatment. This drug may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, start this drug when the expected effect has not been achieved with monotherapy. 1. Replacement therapy: Concomitant therapy with individually dose-adjusted losartan potassium and hydrochlorothiazide may be replaced with this drug. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet containing losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet containing losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet containing losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia even though their blood pressure is controlled at this dose: Treatment may be started with 1 tablet containing losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which can reduce the hydrochlorothiazide dose without reducing the overall blood pressure-lowering effect. Continue to assess the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg; if blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet containing losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose when creatinine clearance is 30 mL/min or higher. Administration to patients with more severe renal impairment is not recommended, as loop diuretics are preferable to thiazide-type drugs in these patients. ○ Patients with hepatic impairment Administration to these patients is not recommended because the initial losartan potassium dose of 25 mg required for patients with hepatic impairment who need dose adjustment cannot be provided with this drug.
Children's dosage
○ Children (under 18 years of age) As there is no experience with use in children and adolescents, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Ingredients

Manufacturer
Bionex Co., Ltd.

Efficacy & effects

Treatment of hypertension not controlled with monotherapy

  • Hypertension
View approved original text

This medication is used in patients with hypertension when blood pressure is not adequately controlled by monotherapy. It helps maintain health by effectively controlling blood pressure and reducing the risk of cardiovascular diseases.

Dosage and Administration

Adult dosage

○ Adults The usual dose of this drug is 1 tablet containing losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg per day are not recommended. The maximum antihypertensive effect generally occurs approximately 3 weeks after the start of treatment. This drug may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, start this drug when the expected effect has not been achieved with monotherapy. 1. Replacement therapy: Concomitant therapy with individually dose-adjusted losartan potassium and hydrochlorothiazide may be replaced with this drug. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet containing losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet containing losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet containing losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia even though their blood pressure is controlled at this dose: Treatment may be started with 1 tablet containing losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which can reduce the hydrochlorothiazide dose without reducing the overall blood pressure-lowering effect. Continue to assess the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg; if blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet containing losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose when creatinine clearance is 30 mL/min or higher. Administration to patients with more severe renal impairment is not recommended, as loop diuretics are preferable to thiazide-type drugs in these patients. ○ Patients with hepatic impairment Administration to these patients is not recommended because the initial losartan potassium dose of 25 mg required for patients with hepatic impairment who need dose adjustment cannot be provided with this drug.

Children's dosage

○ Children (under 18 years of age) As there is no experience with use in children and adolescents, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Precautions

This medication can cause serious harm or death to the fetus and newborn, particularly during pregnancy; therefore, it should be discontinued immediately if pregnancy is confirmed. It should not be used by individuals who are allergic to this medication or those with certain kidney issues, liver disorders, electrolyte imbalances, or anuria. Patients with hypotension, kidney disease, liver disorders, hyperuricemia, diabetes, or cerebrovascular disorders should use this medication with caution and have their condition checked regularly at a doctor's direction. During treatment with this medication, blood pressure, kidney function, and electrolyte levels should be monitored periodically for any abnormal signs. Due to the hydrochlorothiazide component, electrolyte imbalances, particularly hypokalemia or hypercalcemia, may occur; if symptoms arise, consult a doctor immediately. This medication can make the skin sensitive to sunlight, so it is essential to avoid prolonged exposure to UV rays and take precautions to protect the skin. Be cautious when driving or operating machinery, as dizziness or drowsiness may occur. Since this medication can interact with other drugs, all medications currently taken should be disclosed to a physician or pharmacist, especially when combined with potassium supplements, diuretics, or antihypertensives. There is no experience using this medication in children or adolescents, so it is advisable not to administer it to them. Elderly patients may experience adverse reactions more frequently and should use this medication with extra caution. In the case of overdose, hypotension and arrhythmia may occur; seek medical attention immediately. This medication should be stored in its original container, out of reach of children, and with care given to the storage environment.

Side effects

  • Craniosynostosis
  • anuria
  • hypotension
  • renal failure
  • death
  • generalized abdominal pain
  • edema
  • palpitations
  • lumbago
  • dizziness
Show 125 more
  • cough
  • sinusitis
  • upper respiratory tract infection
  • rash
  • angioedema
  • skin peeling phenomenon
  • hemolysis
  • chest pain
  • facial edema
  • fever
  • orthostatic hypotension
  • syncope
  • angina
  • arrhythmia
  • cerebrovascular accident
  • myocardial infarction
  • secondary atrioventricular block
  • anorexia
  • constipation
  • toothache
  • dry mouth
  • dyspepsia
  • flatus
  • gastritis
  • vomiting
  • lethargy
  • anemia
  • gout
  • arm pain
  • arthralgia
  • arthritis
  • fibromyalgia
  • hip pain
  • joint swelling
  • knee pain
  • leg pain
  • muscle cramps
  • muscle weakness
  • musculoskeletal pain
  • myalgia
  • shoulder pain
  • muscle rigidity
  • anxiety
  • anxiety disorder
  • ataxia
  • confusion
  • depression
  • nightmares
  • sensory loss
  • insomnia
  • reduced libido
  • memory impairment
  • migraine
  • neural hyperexcitability
  • panic disorder
  • sensory abnormalities
  • peripheral neuropathy
  • sleep disturbance
  • drowsiness
  • tremor
  • dyspnea
  • epistaxis
  • nasal congestion
  • pharyngeal discomfort
  • respiratory congestion
  • rhinitis
  • venous sinus obstruction
  • chest discomfort
  • alopecia
  • dermatitis
  • dry skin
  • petechiae
  • erythema
  • flushing
  • photosensitivity reaction
  • pruritus
  • sweating
  • urticaria
  • blurred vision
  • ocular pain
  • burning sensation
  • conjunctivitis
  • vision reduction
  • taste disturbance
  • tinnitus
  • erectile dysfunction
  • nocturia
  • frequent urination
  • urinary tract infection
  • weakness
  • pancreatitis
  • jaundice
  • sialadenitis
  • convulsion
  • gastrointestinal irritation
  • aplastic anemia
  • agranulocytosis
  • leukopenia
  • thrombocytopenia
  • purpura
  • necrotizing vasculitis
  • pneumonia
  • pulmonary edema
  • hyperglycemia
  • diabetes
  • hyperuricemia
  • muscle spasms
  • agitation
  • renal failure
  • interstitial nephritis
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • transient blurred vision
  • xanthopsia
  • acute myopia
  • acute closed-angle glaucoma
  • thrombocytopenia
  • vasculitis
  • anaphylactic reaction
  • hepatitis
  • dry cough
  • erythroderma
  • hyperkalemia
  • hyponatremia
  • rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light and should be stored in a tightly sealed container that blocks light. Additionally, it is best stored at room temperature between 1 to 30 degrees Celsius. This storage method helps maintain the medication's effectiveness.

Appearance and packaging

Appearance

Light yellow oval film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.